<DOC>
	<DOCNO>NCT01058850</DOCNO>
	<brief_summary>This research study patient diffuse intrinsic pontine glioma . We hope learn safety efficacy treat pediatric diffuse intrinsic pontine glioma patient EGFRvIII peptide vaccine conventional radiation .</brief_summary>
	<brief_title>Phase I Rindopepimut After Conventional Radiation Children w/ Diffuse Intrinsic Pontine Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Brain Stem Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>3.1.1 Patients must least 3 year age ≤ 18 year age time study enrollment . 3.1.2 Patients must clinical finding neuroradiographic finding consistent diffuse intrinsic pontine glioma . Histologic confirmation diagnosis require diffuse intrinsic pontine glioma . A copy MRI must submit verification eligibility . 3.1.3 Patients must receive conventional radiation therapy total radiation dosage range 5400 6000 cGy administer fraction 150 200 cGy 6 week . 3.1.4 Treatment must start 14 28 day completion conventional radiation 3.1.5 Patients receive systemic corticosteroid therapy must taper stable low ( 2 mg twice daily ) dose dexamethasone two week conventional radiation . 3.1.6 Patients life expectancy must great equal 8 week . 3.1.7 Patients must performance status ( Lansky Karnofsky ) ≥ 50 . 3.1.8 Platelet count ≥ 100,000/ mm3 . 3.1.9 Hemoglobin ≥ 10 g/dL . 3.1.10 Creatinine ≤ 2.0 mg/dL . 3.1.11 Serum bilirubin ≤ 5.0 mg/dL . 3.1.12 If female , patient childbearing potential must negative serum βhCG pregnancy test . 3.1.13 Both male female patient must agree use hormonal barrier birth control spermicidal gel avoid pregnancy study . 3.1.14 The patient and/or guardian must ability understand willingness sign write informed consent document . Exclusion Criteria 3.2.1 Prior therapy diffuse intrinsic pontine glioma , aside surgery , conventional radiation , temozolomide . 3.2.2 Use experimental drug reason within 60 day prior treatment . 3.2.3 Active infection require treatment . 3.2.4 Known medical condition , opinion Investigator , would compromise patient 's ability participate study . This would include chronic active hepatitis infection , know immunosuppressive disease concurrent neurodegenerative disease . 3.2.5 Known allergy hypersensitivity component vaccine treatment , include GMCSF , yeast derived product , history anaphylactic reaction shellfish protein . 3.2.6 Pregnant woman woman breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>